This HTML5 document contains 60 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
foafhttp://xmlns.com/foaf/0.1/
n13http://linked.opendata.cz/resource/drugbank/company/
n12http://linked.opendata.cz/resource/drugbank/drug/DB00197/identifier/chemspider/
n11http://linked.opendata.cz/resource/drugbank/drug/DB00197/identifier/chebi/
n20http://bio2rdf.org/drugbank:
n4http://linked.opendata.cz/resource/drugbank/drug/DB00197/identifier/wikipedia/
admshttp://www.w3.org/ns/adms#
n17http://www.drugs.com/mtm/
n24http://www.rxlist.com/cgi/generic/
n22http://linked.opendata.cz/resource/drugbank/drug/DB00197/identifier/pharmgkb/
n14http://linked.opendata.cz/resource/drugbank/patent/
n19http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
owlhttp://www.w3.org/2002/07/owl#
n23http://linked.opendata.cz/resource/drugbank/drug/DB00197/identifier/pubchem-compound/
n5http://linked.opendata.cz/ontology/drugbank/
n6http://linked.opendata.cz/resource/drugbank/property/
n21http://linked.opendata.cz/resource/drugbank/drug/DB00197/identifier/pubchem-substance/
xsdhhttp://www.w3.org/2001/XMLSchema#
n8http://linked.opendata.cz/resource/drugbank/drug/DB00197/identifier/kegg-drug/
n9http://linked.opendata.cz/resource/drugbank/drug/DB00197/identifier/drugbank/
n7http://linked.opendata.cz/resource/drugbank/drug/DB00197/identifier/iuphar/
n10http://linked.opendata.cz/resource/drugbank/drug/DB00197/identifier/guide-to-pharmacology/

Statements

Subject Item
n2:DB00197
rdf:type
n5:Drug
n5:description
Troglitazone was withdrawn in 2000 due to risk of hepatotoxicity. It was superseded by pioglitazone and rosiglitazone.
n5:generalReferences
# Aljada A, Garg R, Ghanim H, Mohanty P, Hamouda W, Assian E, Dandona P: Nuclear factor-kappaB suppressive and inhibitor-kappaB stimulatory effects of troglitazone in obese patients with type 2 diabetes: evidence of an antiinflammatory action? J Clin Endocrinol Metab. 2001 Jul;86(7):3250-6. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/11443197
n5:group
withdrawn
n5:halfLife
16-34 hours
n5:indication
For the treatment of Type II diabetes mellitus. It is used alone or in combination with a sulfonylurea, metformin, or insulin as an adjunct to diet and exercise.
n5:manufacturer
n13:271B57EF-363D-11E5-9242-09173F13E4C5 n13:271B57EE-363D-11E5-9242-09173F13E4C5
owl:sameAs
n19:DB00197 n20:DB00197
dcterms:title
Troglitazone
adms:identifier
n4:Troglitazone n7:2693 n8:D00395 n9:DB00197 n10:2693 n11:9753 n12:5389 n21:46504655 n22:PA451799 n23:5591
n5:mechanismOfAction
Troglitazone is a thiazolidinedione antidiabetic agent that lowers blood glucose by improving target cell response to insulin. It has a unique mechanism of action that is dependent on the presence of insulin for activity. Troglitazone decreases hepatic glucose output and increases insulin dependent glucose disposal in skeletal muscle. Its mechanism of action is thought to involve binding to nuclear receptors (PPAR) that regulate the transcription of a number of insulin responsive genes critical for the control of glucose and lipid metabolism. Troglitazone is a ligand to both PPARα and PPARγ, with a highter affinity for PPARγ. The drug also contains an α-tocopheroyl moiety, potentially giving it vitamin E-like activity. Troglitazone has been shown to reduce inflammation, and is associated with a decrase in nuclear factor kappa-B (NF-κB) and a concomitant increase in its inhibitor (IκB). NF-κB is an important cellular transcription regulator for the immune response. Unlike sulfonylureas, troglitazone is not an insulin secretagogue.
n5:packager
n13:271B57ED-363D-11E5-9242-09173F13E4C5
n5:patent
n14:5602133 n14:5859037
n5:proteinBinding
> 99% (primarily to serum albumin)
n5:synthesisReference
Krishnamurthi Vyas, Chebiyyam Prabhakar, Sreenivas Dharmaraja Rao, Mamillapalli Ramabadhra Sarma, Om Gaddam Reddy, Rajagopalan Ramanujam, Ranjan Chakrabarti, "Polymorphic forms of troglitazone having enhanced anti-diabetic activity and a process for their preparation." U.S. Patent US5700820, issued June, 1992.
foaf:page
n17:troglitazone.html n24:troglitazone.htm
n5:IUPAC-Name
n6:271B57F4-363D-11E5-9242-09173F13E4C5
n5:InChI
n6:271B57FA-363D-11E5-9242-09173F13E4C5
n5:Molecular-Formula
n6:271B57F9-363D-11E5-9242-09173F13E4C5
n5:Molecular-Weight
n6:271B57F6-363D-11E5-9242-09173F13E4C5
n5:Monoisotopic-Weight
n6:271B57F7-363D-11E5-9242-09173F13E4C5
n5:SMILES
n6:271B57F8-363D-11E5-9242-09173F13E4C5
n5:Water-Solubility
n6:271B57F2-363D-11E5-9242-09173F13E4C5
n5:logP
n6:271B57F0-363D-11E5-9242-09173F13E4C5 n6:271B57F3-363D-11E5-9242-09173F13E4C5 n6:271B580B-363D-11E5-9242-09173F13E4C5
n5:logS
n6:271B57F1-363D-11E5-9242-09173F13E4C5
n5:H-Bond-Acceptor-Count
n6:271B5800-363D-11E5-9242-09173F13E4C5
n5:H-Bond-Donor-Count
n6:271B5801-363D-11E5-9242-09173F13E4C5
n5:InChIKey
n6:271B57FB-363D-11E5-9242-09173F13E4C5
n5:Polar-Surface-Area--PSA-
n6:271B57FC-363D-11E5-9242-09173F13E4C5
n5:Polarizability
n6:271B57FE-363D-11E5-9242-09173F13E4C5
n5:Refractivity
n6:271B57FD-363D-11E5-9242-09173F13E4C5
n5:Rotatable-Bond-Count
n6:271B57FF-363D-11E5-9242-09173F13E4C5
n5:absorption
Absorbed rapidly. Food increases the extent of absorption by 30% to 85%.
n5:affectedOrganism
Humans and other mammals
n5:casRegistryNumber
97322-87-7
n5:Bioavailability
n6:271B5806-363D-11E5-9242-09173F13E4C5
n5:Ghose-Filter
n6:271B5808-363D-11E5-9242-09173F13E4C5
n5:MDDR-Like-Rule
n6:271B5809-363D-11E5-9242-09173F13E4C5
n5:Melting-Point
n6:271B580A-363D-11E5-9242-09173F13E4C5
n5:Number-of-Rings
n6:271B5805-363D-11E5-9242-09173F13E4C5
n5:Physiological-Charge
n6:271B5804-363D-11E5-9242-09173F13E4C5
n5:Rule-of-Five
n6:271B5807-363D-11E5-9242-09173F13E4C5
n5:Traditional-IUPAC-Name
n6:271B57F5-363D-11E5-9242-09173F13E4C5
n5:pKa--strongest-acidic-
n6:271B5802-363D-11E5-9242-09173F13E4C5
n5:pKa--strongest-basic-
n6:271B5803-363D-11E5-9242-09173F13E4C5